First patient dosed in phase I/II MATINS study
(WorldNews Finland)

Faron Pharmaceuticals Ltd (`Faron` or the `Company`) First patient dosed in phase I/II MATINS study of Clevegen TURKU - FINLAND, 14 December 2018 - Faron Pharmaceuticals Ltd (`Faron`) (LON: FARN), the clinical stage biopharmaceutical company, today announces that the first patient has successfully been dosed in its phase I/II MATINS study of Clevegen, its wholly-owned novel precision cancer immunotherapy drug. The study, being initiated now at Helsinki and Oulu University Hospitals in Finland, is a first-in-human open label phase I/II clinical trial to investigate the safety and efficacy of Clevegen in selected metastatic or inoperable solid tumours. Clevegen is a novel anti-Clever-1...